Immunexpress Releases Key Performance Data on SeptiCyte® Lab in PLOS Medicine Publication

Dec 08, 2015, 14:00 ET from Immunexpress, Inc.

SEATTLE, Dec. 8, 2015 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, announced today the publication of the discovery and validation of the SeptiCyte® Lab test for sepsis in PLOS Medicine. SeptiCyte® Lab is a rapid molecular assay that measures a patient's gene expression level to differentiate between sepsis and infection-negative systemic inflammation.

The manuscript describes the identification of a classifier to accurately discriminate sepsis patients from patients with non-septic inflammation and the conversion of the classifier to RT-qPCR format which is the basis of the SeptiCyte® technology. The study details the validation of the technology across five independent patient cohorts and demonstrates clinical performance that outperforms clinical parameters including procalcitonin.

"Current technologies for the diagnosis of sepsis that seek to identify the causative pathogen are slow and frequently result in false negatives," said Roslyn Brandon, President and CEO of Immunexpress. "Our technology, described today in PLOS Medicine, examines the host-response and can provide a probability of sepsis in 100% of cases just a few hours after a physician's initial suspicion of sepsis. We look forward to sharing data from our prospective FDA regulatory trials of SeptiCyte® next year."

About Immunexpress

Immunexpress is a Seattle-based molecular diagnostic company committed to improving outcomes for patients with, or at risk of, sepsis. Immunexpress's SeptiCyte technology quantifies directly from whole blood specific molecular markers from the patient's own immune system – the "host response."  Detecting the host's septic immune response has the potential to identify sepsis earlier and more accurately than current sepsis diagnostics that focus on identifying the invading pathogen.  Immunexpress's pipeline includes monitoring assays for readily available platforms, including point-of-care (POC) sample-to-answer instrumentation.  For more information visit www.Immunexpress.com.

Follow Immunexpress on Twitter at twitter.com/Immunexpress and LinkedIn at www.linkedin.com/company/immunexpress-inc.

Media Contacts:
David Schull or Todd Davenport, Ph.D.
Russo Partners
(212) 845-4271
(212) 845-4262
david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com

SOURCE Immunexpress, Inc.



RELATED LINKS

http://www.Immunexpress.com
http://www.Immunexpress.com